CHRO: Chromocell Therapeutics Corporation Price to Sales
Global conflicts and the disruption of biomaterial logistics are hindering international testing of new drugs. The price-to-sales ratio trend confirms the impact of these factors, where serves as the base parameter value. However, the humanitarian status of biomedicine minimizes sanction threats. The ultimate success of Chromocell Therapeutics (CHRO) depends on the safety of non-opioid analgesics, which determine the company's market potential.
Chromocell Therapeutics Corporation (CHRO) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Chromocell Therapeutics|CHRO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Chromocell|CHRO - Company Aggregate Debts|Debt to Net Assets Ratio Chromocell Therapeutics Corporation|CHRO - Company Long-Term Debts|Short-Term Debt Chromocell Therapeutics|Intermediate Coverage Ratio chromocell.com
- financial results and valuation multiples details:
CHRO - Net Profit|Projected Future Earnings Chromocell Therapeutics|CHRO - Price to Earnings Ratio|Price to Expected Earnings Ratio Chromocell Therapeutics Corp|CHRO - PEG Multiple|Company Value to EBITDA Chromocell Therapeutics Corporation|CHRO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Chromocell Therapeutics|CHRO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months chromocell.com|CHRO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Chromocell Therapeutics
- total revenue and sales volume data:
General company analysis:chromocell.com, CHRO
The P/S ratio determines the market value of a business relative to its annual revenue, allowing an investor to assess the premium paid for every dollar of sales. By analyzing historical P/S trends, one can compare the market capitalization of Chromocell Therapeutics (CHRO) with the efficiency of its non-opioid analgesic R&D, where any deviations in the indicator signal a market reassessment of the prospects for molecule approval by the FDA.
Competing companies
Market Cap to Revenue biogen.com BIIB|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Price to Sales|AXSM - Price-to-Revenue Ratio|ACAD: Price-to-Revenue Ratio|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|VKTX (vikingtherapeutics.com) - Price-to-Revenue Ratio|Market Cap to Revenue SUPN|CPRX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Market Cap to Sales Volume HRMY|P/S Multiple BHVN (Biohaven Ltd.)|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Price to Sales Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CeriBell EEG - Market Capitalization-to-Revenue Ratio|PRTA (Prothena Biosciences) - P/S Multiple|P/S Multiple Alector Therapeutics|Price-to-Revenue Ratio Annexon (ANNX)|OMER: Price-to-Sales Ratio|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA - P/S Multiple|SCLX (Scilex) - Market Cap to Revenue|TVGN: Market Cap to Sales Volume|ACOG (Alpha Cognition Inc) - P/S Multiple|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|P/S Multiple IKT|Market Cap to Revenue cassavasciences.com SAVA|Price-to-Revenue Ratio Assertio ASRT|Price-to-Revenue Coefficient Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - P/S Multiple|Ovid Therapeutics Inc. (OVID) - Market Cap to Revenue|ABOS: P/S Multiple|cervomed.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Price to Sales|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|Price to Sales Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Market Cap to Revenue|NeuroSense Therapeutics Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals|MTVA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeurAxis (NRXS)|HSDT - Price to Sales|P/S Multiple PASG (Passage Bio)|NEUP - Market Cap to Revenue|Minerva Neurosciences - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (athira.com)|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|Alzamend Neuro - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cyclerion Therapeutics Inc.|Price to Sales Protagenic PTIX|Price-to-Revenue Ratio Pasithea Therapeutics (KTTA)|Market Cap to Revenue cortigent.com CRGT|Price-to-Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Price to Sales|Cara Therapeutics, Inc - P/S Multiple|Eliem Therapeutics (ELYM) - Market Cap to Revenue|ITCI: P/S Multiple|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|Price-to-Revenue Ratio NKGN|Price-to-Revenue Ratio NeuroBo (NRBO)|Price-to-Revenue Ratio SAGE (Sage Therapeutics Inc)|Synaptogenix, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TRVN|VIGL: Market Cap to Revenue|anewmeds.com - Market Cap to Sales Volume|CERE: P/S Multiple
